<DOC>
	<DOCNO>NCT01586312</DOCNO>
	<brief_summary>In study want evaluate clinical use allogenic mesenchymal stem cell ( MSC ) , obtain bone marrow healthy donor , treatment knee osteoarthritis . The trial base previous result autologous MSC ( ongoing NCT01183728 trial ) . We propose multicenter , phase I-II clinical trial , prospective , randomize , blind , control treatment osteoarthritis ( degree II III IV ) . The assay consist two arm 15 patient one . Patients experimental arm give intra-articular transplantation allogenic MSC , expand `` Ex Vivo '' GMP-compliant procedure ( MSV , PEI No . 10-134 , authorize Competent Authority ; NCT01183728 ) . In control arm standard treatment intra-articular injection hyaluronic acid shall give . We shall follow evolution pain , disability , quality life quantitative change structure composition cartilage determine T2-weighted MRI relaxation ( Cartigram ) one year .</brief_summary>
	<brief_title>Treatment Knee Osteoarthritis With Allogenic Mesenchymal Stem Cells</brief_title>
	<detailed_description />
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Osteoarthritis , Knee</mesh_term>
	<mesh_term>Hyaluronic Acid</mesh_term>
	<criteria>Knee osteoarthritis grade II , III IV Kellgren Lawrence assess two observer . Chronic knee pain mechanical characteristic . No local systemic septic process . Haematological biochemical analysis without significant alteration contraindicate treatment . Informed write consent patient . The patient able understand nature study Age 75 18 year legally dependent Present Infection ( include study sign infection must evidence ) Congenital acquire malformation result significant deformity knee ( varus &lt; 10ยบ ; valgus &lt; 20ยบ ) lead problem application evaluation result . Overweight express body mass index ( BMI ) great 30.5 ( obesity grade II ) . BMI estimate mass ( kg ) / corporal surface ( m2 ) . Women pregnant intend become pregnant breastfeed Neoplasia Immunosuppressive state Intraarticular infiltartion treatment last 3 month previous study inclusion Participation another clinical trial treatment different investigational product within 30 day prior inclusion study . Other pathologic condition circumstance difficult participation study accord medical criterion</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>Knee degenerative disease</keyword>
	<keyword>osteoarthritis</keyword>
	<keyword>gonarthrosis</keyword>
	<keyword>stem cell</keyword>
	<keyword>cellular therapy</keyword>
	<keyword>regenerative therapy</keyword>
	<keyword>Mesenchymal stem cell</keyword>
	<keyword>Bone marrow</keyword>
	<keyword>musculoskeletal Diseases</keyword>
	<keyword>Mesenchymal Stromal Cells ( allogenic )</keyword>
</DOC>